NRX Pharmaceuticals, Inc. Deferred Tax Assets, Unrealized Losses on Trading Securities
NRX Pharmaceuticals, Inc. (NRXP) had Deferred Tax Assets, Unrealized Losses on Trading Securities of $0 as of 2020-12-31, per its 10-K/A filed 2021-05-14.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities · last filed 2021-05-14
- 2020-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $0.00.
- 2019-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $0.00.
- 2018-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $0.00.
- 2017-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $995.00.
| Period end | Deferred Tax Assets, Unrealized Losses on Trading Securities |
|---|---|
| 2020-12-31 | $0.00 10-K/A · filed 2021-05-14 |
| 2019-12-31 | $0.00 10-K/A · filed 2021-05-14 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-30 |
| 2017-12-31 | $995.00 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |